ArticleAnnals of surgical oncology2026
Raised Serum Tumour Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRaised serum tumour markers are a prognostic factor in advanced colorectal cancer. The purpose of the current study was to evaluate the role of elevation of carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125) and carbohydrate antigen (CA 19.9), with a focus on burden of peritoneal disease, incomplete cytoreduction, and survival in patients with colorectal peritoneal metastases (CPM) treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
methodsThis is a retrospective analysis of a prospectively collected database. Patients with CPM treated by CRS and HIPEC in a single high-volume centre between 2000-2021 with complete demographic, tumour marker status, histopathological, and follow-up information were included.
resultsIn total, 433 patients were included, of which 232 (53.6%) were female. The median age was 59 years, and the median peritoneal cancer index (PCI) was 6. Overall, 268/433 (61.9%) patients had one or more elevated tumour markers. Elevated tumour markers were associated with higher PCI and higher risk of receiving incomplete cytoreduction (odds ratio [OR] 2.8, p = 0.026 and OR 6.21, p < 0.001 for two and three elevated markers, respectively). Furthermore, elevated tumour markers were associated with worse 5-year overall survival (overall survival, hazard ratio 1.55, p = 0.021; 2.85, p < 0.001; and 2.85, p < 0.001 for any one, any two, or all three elevated markers, respectively) and disease-free survival at multivariable analysis.
conclusionsElevated preoperative tumour markers correlate with extent of CPM, a higher risk of incomplete cytoreduction, and decreased overall survival and disease-free survival.
Indexed as
Identifiers
41547693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.